Bone Marrow Transplant 2018 Jun 08
Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy?
ABSTRACT
Related Questions
Especially with the current drug shortage of nelarabine.
New answer by Medical Oncologist at H Lee Moffitt Cancer Center (August 31, 2021)
The answer is always clinical trial if feasible. If only commercial options: Assuming morphologic relapse, I tend to favor peg-asp containing regimen if the patient is fit eno...